119 related articles for article (PubMed ID: 24989481)
41. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.
Holleran BJ; Beaulieu ME; Proulx CD; Lavigne P; Escher E; Leduc R
Biochem J; 2007 Feb; 402(1):51-61. PubMed ID: 17064254
[TBL] [Abstract][Full Text] [Related]
42. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
[TBL] [Abstract][Full Text] [Related]
43. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
[TBL] [Abstract][Full Text] [Related]
44. GPCR structure-based virtual screening approach for CB2 antagonist search.
Chen JZ; Wang J; Xie XQ
J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
[TBL] [Abstract][Full Text] [Related]
45. Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach.
Kesharwani RK; Singh DV; Misra K
J Vector Borne Dis; 2013; 50(2):93-102. PubMed ID: 23995310
[TBL] [Abstract][Full Text] [Related]
46. Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity.
Pandey A; Paliwal S; Yadav R; Paliwal S
Curr Comput Aided Drug Des; 2015; 11(4):361-73. PubMed ID: 26694105
[TBL] [Abstract][Full Text] [Related]
47. Effective Use of Empirical Data for Virtual Screening against APJR GPCR Receptor.
Manoliu LCE; Martin EC; Milac AL; Spiridon L
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443478
[TBL] [Abstract][Full Text] [Related]
48. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
49. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations.
Matsoukas MT; Cordomí A; Ríos S; Pardo L; Tselios T
J Chem Inf Model; 2013 Nov; 53(11):2874-83. PubMed ID: 24090110
[TBL] [Abstract][Full Text] [Related]
50. Extended template-based modeling and evaluation method using consensus of binding mode of GPCRs for virtual screening.
Sato M; Hirokawa T
J Chem Inf Model; 2014 Nov; 54(11):3153-61. PubMed ID: 25350693
[TBL] [Abstract][Full Text] [Related]
51. Characterizing common substructures of ligands for GPCR protein subfamilies.
Erguner B; Hattori M; Goto S; Kanehisa M
Genome Inform; 2010; 24():31-41. PubMed ID: 22081587
[TBL] [Abstract][Full Text] [Related]
52. The 3D Structure of Human DP Prostaglandin G-Protein-Coupled Receptor Bound to Cyclopentanoindole Antagonist, Predicted Using the DuplexBiHelix Modification of the GEnSeMBLE Method.
Shankar V; Goddard WA; Kim SK; Abrol R; Liu F
J Chem Theory Comput; 2018 Mar; 14(3):1624-1642. PubMed ID: 29268008
[TBL] [Abstract][Full Text] [Related]
53. New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding.
Lupala CS; Gomez-Gutierrez P; Perez JJ
J Comput Aided Mol Des; 2016 Jan; 30(1):85-101. PubMed ID: 26697880
[TBL] [Abstract][Full Text] [Related]
54. Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H
Naporra F; Gobleder S; Wittmann HJ; Spindler J; Bodensteiner M; Bernhardt G; Hübner H; Gmeiner P; Elz S; Strasser A
Pharmacol Res; 2016 Nov; 113(Pt A):610-625. PubMed ID: 27697645
[TBL] [Abstract][Full Text] [Related]
55. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets?
Bissantz C; Bernard P; Hibert M; Rognan D
Proteins; 2003 Jan; 50(1):5-25. PubMed ID: 12471595
[TBL] [Abstract][Full Text] [Related]
56. Discovery of high affinity ligands for β2-adrenergic receptor through pharmacophore-based high-throughput virtual screening and docking.
Yakar R; Akten ED
J Mol Graph Model; 2014 Sep; 53():148-160. PubMed ID: 25137647
[TBL] [Abstract][Full Text] [Related]
57. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
[TBL] [Abstract][Full Text] [Related]
58. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.
Patny A; Desai PV; Avery MA
Proteins; 2006 Dec; 65(4):824-42. PubMed ID: 17034041
[TBL] [Abstract][Full Text] [Related]
59. Large scale free energy calculations for blind predictions of protein-ligand binding: the D3R Grand Challenge 2015.
Deng N; Flynn WF; Xia J; Vijayan RS; Zhang B; He P; Mentes A; Gallicchio E; Levy RM
J Comput Aided Mol Des; 2016 Sep; 30(9):743-751. PubMed ID: 27562018
[TBL] [Abstract][Full Text] [Related]
60. Enrichment factor analyses on G-protein coupled receptors with known crystal structure.
Anighoro A; Rastelli G
J Chem Inf Model; 2013 Apr; 53(4):739-43. PubMed ID: 23484900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
